People: Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

1:30am IST
Change (% chg)

$0.34 (+0.65%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Klassen, Preston 

Dr. Preston S. Klassen M.D. M.H.S. is an Executive Vice President - Research & Development, Chief Medical Officer of the Company. Dr. Klassen has served as our Executive Vice President, Research and Development and Chief Medical Officer since March 2017. Most recently, he was Chief Medical Officer of Laboratoris Sanifit S.L. from May 2016 to March 2017, and was Executive Vice President, Head of Global Development at Orexigen Therapeutics, Inc. from November 2009 to May 2016. Previously, Dr. Klassen held several positions of increasing responsibility at Amgen Inc., including Therapeutic Area Head for Nephrology. Prior to joining Amgen, he was a faculty member in the Division of Nephrology at Duke University Medical Center. In March 2018, Orexigen filed a voluntary Chapter 11 petition in the United States Bankruptcy Court for the District of Delaware. Dr. Klassen serves on the board of Conatus Pharmaceuticals Inc., a biotechnology company focused on developing and commercializing novel medicines to treat liver disease. Dr. Klassen received his medical degree from the University of Nebraska College of Medicine and completed his residency in internal medicine, fellowship in nephrology, and masters in health sciences degree at Duke University.

Basic Compensation

Total Annual Compensation, USD 667,369
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,412,480
Fiscal Year Total, USD 3,079,840

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Tina Nova


Amit Munshi


Kevin Lind


Steven Spector


Vincent Aurentz


Preston Klassen

As Of  31 Dec 2018